EUVIMEDDescobrir EUVIMED
Open access · CC BY 4.0

Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection

Marco Ratta iD, Donia Skanji, Zhaoyang Teng iD, Gaëlle Saint-Hilary iD, Mauro Gasparini iD, Pavel Mozgunov iD

Statistics in Medicine · 2026-11 · 45 (25-27)

DOI: 10.1002/sim.70790 ↗

At a glance

Journal article in Statistics in Medicine, published online on 2026-11-16. Written by Marco Ratta and 5 co-authors. Institution: Dipartimento di Scienze Matematiche, Politecnico di Torino, Torino, Italy. Major MEDLINE topics: Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Research Design. 51 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council, National Institute for Health and Care Research.

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Seamless Phase II/III designs are increasingly employed to accelerate drug development, particularly in settings where multiple doses of the same compound need to be evaluated in parallel. In such designs, a restricted subset of doses is selected at the first stage of the trial and subsequently carried forward to the second stage, where efficacy is assessed against control. Dose selection is typically based on a single efficacy endpoint, ensuring consistency between interim decision‐making and final hypothesis testing. However, safety is typically not formally integrated into the selection process during the design stage, which can be problematic, as it may lead to advancing doses that are effective but potentially harmful. In this work, we propose a novel multi‐arm two‐stage design in which the dose with the most favorable benefit‐risk profile at the interim analysis is selected and continued into Phase III. Benefit‐risk assessment is conducted using probabilistic multi‐criteria decision analysis (MCDA), where information from multiple efficacy and safety endpoints is combined into a single aggregated score. For the proposed design, we derive an analytical expression for the decision boundary, ensuring strong control of the Type I error rate, and provide guidance on sample size determination. The operating characteristics are evaluated through extensive simulation studies and compared with existing designs from the literature, demonstrating that the proposed approach is particularly effective in terminating potentially harmful doses at an early stage.

Subjects

MeSH terms (MEDLINE)

Clinical Trials, Phase II as TopicClinical Trials, Phase III as TopicResearch DesignHumansRisk AssessmentDose-Response Relationship, DrugDecision Support TechniquesEndpoint DeterminationComputer SimulationModels, Statistical

Author keywords

multiplicitymulti‐criteria decision analysisquantitative benefit‐risk assessmentseamless designs

Authors and institutions

  • Dipartimento di Scienze Matematiche, Politecnico di Torino, Torino, Italy.
  • Department of Statistical Methodology, Saryga, Tournus, France.
  • Servier National Research Institute (IRIS), Servier, Gif-sur-Yvette, France.
  • Astellas Pharma, Boston, Massachussets, USA.
  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

ORCID profiles: Marco Ratta, Zhaoyang Teng, Gaëlle Saint-Hilary, Mauro Gasparini, Pavel Mozgunov

Funding

  • Medical Research Council
  • National Institute for Health and Care Research

Cite

APA

Ratta, M., Skanji, D., Teng, Z., Saint-Hilary, G., Gasparini, M., & Mozgunov, P. (2026). Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection. Statistics in Medicine, 45(25-27). https://doi.org/10.1002/sim.70790

Vancouver

Ratta M, Skanji D, Teng Z, Saint-Hilary G, Gasparini M, Mozgunov P. Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection. Statistics in Medicine. 2026;45(25-27). doi:10.1002/sim.70790

BibTeX
@article{Ratta2026,
  author = {Ratta, Marco and Skanji, Donia and Teng, Zhaoyang and Saint-Hilary, Gaëlle and Gasparini, Mauro and Mozgunov, Pavel},
  title = {Including Quantitative Benefit‐Risk Assessment in Seamless Phase 2/3 Designs With Dose Selection},
  journal = {Statistics in Medicine},
  year = {2026},
  volume = {45},
  number = {25-27},
  doi = {10.1002/sim.70790}
}
Start for free →